Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma
- 1 November 2019
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 207, 62-70
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular AreaOphthalmic Plastic & Reconstructive Surgery, 2015
- Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus SyndromeAmerican Journal of Ophthalmology, 2015
- Identifying Locally Advanced Basal Cell Carcinoma Eligible for Treatment with Vismodegib: An Expert Panel ConsensusFuture Oncology, 2015
- Vismodegib-associated hepatotoxicity: A potential side effect detected in postmarketing surveillanceJournal of the American Academy of Dermatology, 2014
- Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomasWorld Journal of Clinical Cases, 2014
- Vismodegib for Periocular and Orbital Basal Cell CarcinomaJAMA Ophthalmology, 2013
- Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell CarcinomaOphthalmic Plastic & Reconstructive Surgery, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- A systematic review of worldwide incidence of nonmelanoma skin cancerBritish Journal of Dermatology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009